- Accelerates wound closure and improves wound healing
KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company") (OTCQB:PVCT) today announced that non-clinical data on Provectus's proprietary, pharmaceutical-grade, rose bengal sodium ("RBS") active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology ("SID"), held May 15-18, 2024 in Dallas, Texas.
This work is part of research being conducted by Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston ("UTMB").